An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

• Published in: Japanese journal of clinical oncology Vol. 51; no. 3; pp. 484 - 491
• Main Authors: Mosca, Alessandra, De Giorgi, Ugo, Procopio, Giuseppe, Basso, Umberto, Cartenì, Giacomo, Bersanelli, Melissa, Naglieri, Emanuele, Galli, Luca, Caffo, Orazio, Fornarini, Giuseppe, Boccardo, Francesco, Porta, Camillo
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 03.03.2021
• Subjects: Adult; Aged; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - radiotherapy; Carcinoma, Renal Cell - surgery; Databases, Factual; Female; Humans; Italy; Kaplan-Meier Estimate; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Retrospective Studies; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Treatment Outcome; Italy; real-world effectiveness; first-line therapy; metastatic renal cell carcinoma; vascular endothelial growth factor receptor tyrosine kinase inhibitors; pazopanib

Abstract Objective Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastati...